Mesenchymal stem cells engineered to express vasoactive intestinal peptide (VIP) halted disease progression in a chronic MS mouse model when given at peak disease — while neither VIP alone nor unmodified stem cells were effective at that stage.
Effective only as a combinationVIP-expressing MSCs stopped chronic MS progression at peak disease in mice — but neither VIP gene therapy alone nor unmodified MSCs achieved this, demonstrating essential synergy between peptide and cellular therapy
What the researchers found
MSCs engineered to express VIP stopped disease progression and reduced symptoms in chronic EAE when given at peak disease. Improvements included decreased anti-MOG T cell responses, reduced CNS inflammation and demyelination, and preserved neuronal integrity. Neither VIP gene therapy alone nor unmodified MSCs were effective at peak disease — only the combination worked.
Why it matters
Chronic and progressive MS have no effective treatments. Combining stem cell therapy with VIP peptide delivery addresses both immunoregulation and neuroprotection simultaneously, working even at advanced disease stages where current therapies fail.
The numbers in context
3.3 kDa VIP peptide; MOG-EAE chronic model; IP administration; effective at peak disease; neither VIP vectors alone nor unmodified MSCs effective alone
How the study worked
Allogeneic MSCs were transduced with lentiviral vectors to express processed VIP. Cells were administered intraperitoneally in mice with MOG-induced chronic EAE at peak disease. Outcomes included clinical scoring, peripheral T cell responses, and CNS histopathology (inflammation, demyelination, neuronal integrity). Controls included unmodified MSCs and VIP lentiviral vectors alone.
What this study cannot tell us
Mouse EAE model may not fully represent human MS pathology. Only intraperitoneal delivery tested. Long-term durability of therapeutic effect not characterized. Lentiviral modification of MSCs raises gene therapy safety considerations. Small animal numbers typical of EAE studies.
How to read the evidence
This is a preclinical study in a well-established MS mouse model with appropriate controls (VIP alone, MSCs alone, combination). The demonstration that only the combination works at peak disease is a strong mechanistic finding, though translation to human MS requires further development.
When this study was published
Published in 2013, this study pioneered the concept of VIP-expressing MSCs for MS. The approach has influenced ongoing research into engineered cell therapies for autoimmune neurological diseases.
The bigger picture
This study demonstrates the power of combining cell therapy with peptide biology. VIP is a potent anti-inflammatory and neuroprotective peptide, but delivering it to the right locations at therapeutic levels has been challenging. Using stem cells as living vehicles solves this — they naturally migrate to sites of inflammation and can continuously produce VIP where it's needed most. The finding that the combination works at advanced disease when neither component works alone is particularly significant for progressive MS, where treatment options are desperately needed.
Questions still open
- Could VIP-expressing MSCs be developed as a clinical therapy for progressive MS patients who don't respond to current treatments?
- How long do the VIP-expressing MSCs survive and continue producing VIP after transplantation?
- Would this approach work for other autoimmune neurological conditions like neuromyelitis optica?
Common questions
What is VIP and how does it help MS?
Why were stem cells needed if VIP is the therapeutic molecule?
Read the original research
Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis.
Cell transplantation, 22(5), 839-54
Citation
Cobo, Marién; Anderson, Per; Benabdellah, Karim; Toscano, Miguel G; Muñoz, Pilar; García-Pérez, Angélica; Gutierrez, Iván; Delgado, Mario; Martin, Francisco. (2013). Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis.. Cell transplantation, 22(5), 839-54.